Hepatology (Liver, Pancreatic, Gall Bladder) | IND Enabling Drugs

Ascletis Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CHINA China

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA

Lead Product(s): ASC41,ASC40

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: IND Enabling Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 17, 2020

Details:

ASC41 is expected to be used in combination with ASC40, another innovative drug of the Company, for treatment of NASH.

Theraly Fibrosis

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Theraly Fibrosis Awarded $3.9 Million SBIR Phase II Grant to Support Development of TLY012 for Chronic Pancreatitis

Lead Product(s): TLY012

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: National Institutes of Health

Deal Size: $5.9 million Upfront Cash: Undisclosed

Deal Type: Funding January 30, 2020

Details:

Theraly Fibrosis has been awarded a Small Business Innovation Research Phase II grant by the National Institutes of Health to support development of TLY012 for treatment of chronic pancreatitis.

Enleofen Bio Pte

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Singapore

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Lead Product(s): Enx108A

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)

Highest Development Status: IND Enabling Product Type: Large molecule

Partner/Sponsor/Collaborator: Boehringer Ingelheim

Deal Size: $1,000.0 million Upfront Cash: $1,000.0 million

Deal Type: Partnership January 09, 2020

Details:

Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio.

Find

Find FDA Investigational New Drug (IND) Submissions for Hepatology (Liver, Pancreatic, Gall Bladder)

IND Enabling

A collaboration with SCORR Marketing

Product Type

Companies

Ascletis Pharma

Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA

Theraly Fibrosis

Theraly Fibrosis Awarded $3.9 Million SBIR Phase II Grant to Support Development of TLY012 for Chronic Pancreatitis

Enleofen Bio Pte

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases